These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 28408007)

  • 21. An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D.
    Feng Y; Herdman M; van Nooten F; Cleeland C; Parkin D; Ikeda S; Igarashi A; Devlin NJ
    Qual Life Res; 2017 Aug; 26(8):2067-2078. PubMed ID: 28343350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EQ-5D-5L norms for the urban Chinese population in China.
    Yang Z; Busschbach J; Liu G; Luo N
    Health Qual Life Outcomes; 2018 Nov; 16(1):210. PubMed ID: 30409137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
    Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
    Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores?
    Luo N; Cheung YB; Ng R; Lee CF
    Health Qual Life Outcomes; 2015 Oct; 13():166. PubMed ID: 26438167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population.
    Petrou S; Hockley C
    Health Econ; 2005 Nov; 14(11):1169-89. PubMed ID: 15942981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients.
    Pan CW; Sun HP; Wang X; Ma Q; Xu Y; Luo N; Wang P
    Qual Life Res; 2015 Jul; 24(7):1767-74. PubMed ID: 25540029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set.
    Grochtdreis T; Dams J; König HH; Konnopka A
    Eur J Health Econ; 2019 Aug; 20(6):933-944. PubMed ID: 31030292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference.
    Nolan CM; Longworth L; Lord J; Canavan JL; Jones SE; Kon SS; Man WD
    Thorax; 2016 Jun; 71(6):493-500. PubMed ID: 27030578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D.
    Fogarty E; Walsh C; Adams R; McGuigan C; Barry M; Tubridy N
    Mult Scler; 2013 Aug; 19(9):1190-6. PubMed ID: 23401128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.
    Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA
    Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life in amyotrophic lateral sclerosis using EQ-5D-5L.
    Wei QQ; Hou Y; Chen Y; Ou R; Cao B; Zhang L; Yang T; Shang H
    Health Qual Life Outcomes; 2021 Jul; 19(1):181. PubMed ID: 34284776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma.
    Bharmal M; Hunger M; Schlichting M
    Value Health; 2019 Oct; 22(10):1170-1177. PubMed ID: 31563260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L.
    Martin A; Meads D; Griffiths AW; Surr CA
    Value Health; 2019 Dec; 22(12):1417-1426. PubMed ID: 31806199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
    Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
    Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the EQ-5D-5L, EQ-VAS stand-alone component and Oxford knee score in the Australian knee arthroplasty population utilising minimally important difference, concurrent validity, predictive validity and responsiveness.
    Lin DY; Cheok TS; Kaambwa B; Samson AJ; Morrison C; Chan T; Kroon HM; Jaarsma RL
    Health Qual Life Outcomes; 2023 May; 21(1):41. PubMed ID: 37165364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dutch Tariff for the Five-Level Version of EQ-5D.
    M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
    Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.